New MGA Report Presents Biosimilar Market Opportunities in Ophthalmology
MGA releases a new report, “Biosimilar Market Opportunities in Ophthalmology.” Authored by founder and CEO Alex Brill, the report examines current trends and economics in the ophthalmology industry. Brill discusses lessons learned in other biosimilar markets. He also shares how to use these lessons to unlock the potential of ophthalmology biosimilars. The healthcare system could see significant savings as the first ophthalmology biosimilars enter the US market. Industry stakeholders need to be ready to overcome barriers to early adoption to increase access for deserving patients. Educating ophthalmologists, practice administrators, payers, and patients on the safety and efficacy of biosimilars will help support their early adoption.
Click here to read the full report on the MGA website.
